CSL Limited
ASX: CSL
Robust plasma therapy demand and double-digit profit growth.
(Source: TradingView) 3-Month Performance Profile of CSL on a DTF compared to S&P/ASX 200 (XJO).
CSL reported a resilient FY25, supported by strong demand across its plasma-derived therapy portfolio. Growth in immunoglobulins, haemophilia treatments, albumin and peri-operative bleeding products continued to lif
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
